Maternal body weights were reduced in the highest-dose group (plasma level approximately 500 times the level achieved in humans using a transdermal system). There may be new information. Transderm-Scop (scopolamine) is well tolerated. There may be new information. The average plasma concentration produced is 87 pg/mL (0.28 nM) for free scopolamine and 354 pg/mL for total scopolamine (free + conjugates). [See USP Controlled Room Temperature. Do not give scopolamine transdermal system to other people, even if they have the same symptoms you have. Does Scopolamine Base Transdermal System Interact with other Medications? https://www.webmd.com/drugs/2/drug-14032/scopolamine-transdermal Do not cut the transdermal system.Store upright at 20° to 25°C (68° to 77°F). The onset of these symptoms, generally 24 hours or more after the transdermal system has been removed, can be severe and may require medical intervention The signs and symptoms of anticholinergic toxicity include: lethargy, somnolence, coma, confusion, agitation, hallucinations, convulsion, visual disturbance, dry flushed skin, dry mouth, decreased bowel sounds, urinary retention, tachycardia, hypertension, and supraventricular arrhythmias. This information does not take the place of talking to your doctor about your medical condition or your treatment.To help prevent nausea and vomiting from motion sickness:Inside the scopolamine transdermal system package, you will find one scopolamine transdermal system. Available for Android and iOS devices. The dose of this medicine will be different for different patients. Less than 10% of the total dose is excreted in the urine as the parent drug and metabolites over 108 hours.No long-term studies in animals have been conducted to evaluate the carcinogenic potential of scopolamine. It crosses the placenta and the blood brain barrier and may be reversibly bound to plasma proteins.Scopolamine is metabolized and conjugated with less than 5% of the total dose appearing unchanged in the urine. Select one or more newsletters to continue. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.The concurrent use of scopolamine transdermal system with other drugs that cause CNS adverse reactions of drowsiness, dizziness or disorientation (e.g., sedatives, hypnotics, opiates, anxiolytics and alcohol) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may potentiate the effects of scopolamine transdermal system Concomitant use of scopolamine with other drugs having anticholinergic properties may increase the risk of CNS adverse reactions Scopolamine transdermal system, as an anticholinergic, may delay gastric and upper gastrointestinal motility and, therefore, the rate of absorption of other orally administered drugs. Do not use scopolamine transdermal system for a condition for which it was not prescribed. Following removal of the used transdermal system, there is some degree of continued systemic absorption of scopolamine bound in the skin layers.The distribution of scopolamine is not well characterized. Avoid use of scopolamine transdermal system in pregnant women with severe preeclampsia because eclamptic seizures have been reported after exposure to scopolamine In animal studies, there was no evidence of adverse developmental effects with intravenous administration of scopolamine hydrobromide revealed in rats. Scopolamine is (αS)-α-(hydroxymethyl)benzeneacetic acid (1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0Scopolamine has a molecular weight of 303.35 and a pKa of 7.55-7.81. These are not all the possible side effects of scopolamine transdermal system.Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. There are no available data on the effects of scopolamine on the breastfed infant or the effects on milk production. The brown imprinting ink contains acrylic polymers, carbon black, iron oxides (red and yellow), polydimethylsiloxane, polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, sodium dioctyl sulfosuccinate and triethanolamine.For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX).Read this Instructions for Use before you start using scopolamine transdermal system and each time you get a refill. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function.The system is formulated to deliver approximately 1 mg of scopolamine to the systemic circulation over 3 days.Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.